Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | HTR1D | P28221 | 2/20 | 0.51 |
| ▸ | HTR1B | P28222 | 2/20 | 0.51 |
| ▸ | HTR1F | P30939 | 2/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2314301 | 0.87 | HTR6 (0.51) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL2013231 | 0.82 | CPT1A (0.47) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL2010391 | 0.81 | HTR6 (0.43) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL2009634 | 0.78 | HTR6 (0.46) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL2003719 | 0.74 | HTR6 (0.47) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL1972822 | 0.73 | HTR6 (0.56) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL4783590 | 0.73 | HTR6 (0.68) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL2271799 | 0.73 | HTR6 (0.55) | HTR6HTR1ADRD2HTR7PDE5A | |
| SCHEMBL2008525 | 0.73 | HTR6 (0.57) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL2007580 | 0.71 | HTR6 (0.47) | HTR6HTR1ADRD2HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200980-B9 | AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS FIELD OF INVENTION | SUVEN LIFE SCIENCES LTD (IN) | 2011-12-28 | — | — | EP | claimed |
| US-7964627-B2 | Amino arylsulfonamide compounds and their use as 5-HT6 ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | claimed |
| US-20100216861-A1 | AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-08-26 | — | — | US | claimed |
| US-7964627-B2 | Amino arylsulfonamide compounds and their use as 5-HT6 ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-20100216861-A1 | AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216861-A1 | AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR5A, HTR1A | HTR6 1/4885HTR1A 3/4885DRD2 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.